Literature DB >> 25902186

Aortic Dissection: Accurate Subintimal Flap Fenestration by Using a Reentry Catheter with Fluoroscopic Guidance-Initial Single-Institution Experience.

Franziska Wolfschmidt1, Nicole Hassold1, Jan Peter Goltz1, Rainer Leyh1, Thorsten Alexander Bley1, Ralph Kickuth1.   

Abstract

PURPOSE: To evaluate the feasibility, effectiveness, and safety of using a commercially available reentry catheter with fluoroscopic guidance to gain controlled target lumen reentry for fenestration in patients with aortic dissection.
MATERIALS AND METHODS: This retrospective study was approved by the local institutional review board; informed consent was waived. Between April 2009 and December 2013, 13 consecutive patients (10 men and three women; mean age, 51.2 years; range, 30.0-77.0 years; mean age of women, 47.0 years; range, 30.0-69.0 years; mean age of men, 52.4 years; range, 35.0-77.0 years) with aortic dissection and spinal (n = 4), renal (n = 7), mesenteric (n = 2), and/or iliofemoral (n = 9) malperfusion syndrome were included. All patients received target lumen reentry by means of balloon fenestration of the aortic dissection flap. A reentry catheter was used for fluoroscopically guided puncture of the target lumen. Technical success, clinical outcome, Stanford type of dissection, procedure time, number of fenestrations of the intimal flap per patient, necessity of additional aortic stent-graft implantation and/or placement of a bare metal stent, complications, and follow-up images were evaluated. Pre- and postinterventional systolic blood pressure gradients between the true lumen and the false lumen were compared (Wilcoxon signed-rank test). Safety of the reentry catheter maneuver was estimated with the Clopper-Pearson method.
RESULTS: Use of the reentry catheter was technically successful in all 13 (100%) patients and clinically successful in 10 of 13 (77%) patients. Four patients had type A and nine had type B dissection. The mean clinical follow-up period was 14.2 months. Median procedure time was 71 minutes. In four patients, fenestration of the intimal flap was performed twice. Three patients underwent additional aortic stent grafting, four patients underwent placement of an iliofemoral stent, and one patient underwent placement of a carotid artery stent. Blood pressure gradients between the true lumen and the false lumen were significantly reduced (P = .0313). One patient who had a combination of syndromes died of multiorgan failure.
CONCLUSION: The applied commercially available reentry catheter seems to be a reliable and safe tool that may be useful for gaining target lumen reentry with reasonably good clinical outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 25902186     DOI: 10.1148/radiol.2015140520

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Conservatively treated coronary malperfusion associated with acute type A dissection before aortic root replacement.

Authors:  Sokichi Kamata; Toshihiro Funatsu; Yoshito Itou; Toshikatsu Yagihara
Journal:  J Cardiol Cases       Date:  2017-10-04

2.  Targeted tibio-peroneal re-entry during subintimal revascularization using the Outback® catheter.

Authors:  K Rippel; H Ruhnke; B Jehs; J Decker; T Kroencke; C Scheurig-Muenkler
Journal:  CVIR Endovasc       Date:  2021-01-28

3.  Color-coded summation images for the evaluation of blood flow in endovascular aortic dissection fenestration.

Authors:  Anne Marie Augustin; Franziska Wolfschmidt; Thilo Elsässer; Alexander Sauer; Alexander Dierks; Thorsten Alexander Bley; Ralph Kickuth
Journal:  BMC Med Imaging       Date:  2022-02-04       Impact factor: 1.930

4.  In Situ Laser Fenestration Is a Feasible Method for Revascularization of Aortic Arch During Thoracic Endovascular Aortic Repair.

Authors:  Jinbao Qin; Zhen Zhao; Ruihua Wang; Kaichuang Ye; Weimin Li; Xiaobing Liu; Guang Liu; Chaoyi Cui; Huihua Shi; Zhiyou Peng; Fukang Yuan; Xinrui Yang; Min Lu; Xintian Huang; Mier Jiang; Xin Wang; Minyi Yin; Xinwu Lu
Journal:  J Am Heart Assoc       Date:  2017-04-21       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.